AddLife shares went into yesterday's Q3 2026 release on a strong run, with the stock up about 22% over the past three months and closing at SEK190.6. The headline from the quarter is clear: Sales reached SEK2,599m and net income came in at SEK127m, numbers that land into a healthcare distributor already priced for progress.
Short term traders are focused on a rich P/E of 36.1x and a balance sheet flagged for high debt. Longer term investors are weighing that leverage against a discounted valuation versus peers and the reliance on a sizeable one off gain in the recent earnings history.
Love AddLife's earnings momentum but concerned about that rich P/E and elevated leverage? Filter for healthcare distributors that pair solid profitability with stronger balance sheets using the list of solid balance sheet and fundamentals stocks (203 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):SEK2,599m vs. SEK2,429m (up about 7%)
-
Net Income, excl. extra items (Q3 2026 vs Q3 2025):SEK127m vs. SEK81m (up about 57%)
-
Basic EPS (Q3 2026 vs Q3 2025):SEK1.04 vs. SEK0.66 (up about 57%)
-
Trailing 12-month Net Margin (Q3 2026 vs prior year):6.0% vs. 3.7% (margin higher year on year, supported by a SEK154m one off gain)
Earnings tell part of the story, but investors who care about what they are actually paying for usually study the cash flowing through AddLife before judging the current share price. On AddLife's recent numbers, if you focus only on the cash coming in and out of the business, the stock could be a solid 16% undervalued .
AddLife's Margin Ambitions Meet Early Proof Points
The bullish story hinges on AddLife turning product pruning and deal making into higher quality earnings.
"AddLife is prioritizing organic growth and profitability improvements through initiatives such as optimizing their product portfolio by removing less profitable products, which is expected to enhance gross margins and overall earnings."
Q3 fits that script. Gross margin improved by about 1 percentage point and adjusted EBITA margin reached 11.5%, with year to date at 12.2% versus 11.9% last year. Labtech, where tender wins and advanced products are concentrated, lifted its EBITA margin to 12.9%. Recent acquisitions such as Unicam and Lehnen are described as carrying higher than group margins, which supports the mix upgrade narrative.
Testing AddLife's End Market And Cash Flow Fears
The bear case worries that weak funding and working capital strain will undercut AddLife's story.
"AddLife is facing some market hesitation regarding investment in academic research, which could affect future revenue growth if funding in this area does not improve."
Q3 shows only partial support for that concern. Organic growth of roughly 4% indicates demand is still there, although Labtech organic growth of 2% reflects softer research and seasonal effects after an unusually strong prior Q3. On cash generation, the worry about product launches hitting working capital did not dominate this quarter. Operating cash flow rose 62% and leverage sits at 2.5x, below the 3x target, suggesting current investment is still manageable.
Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there .
Hunt For Quiet Margin Stories
Consider how AddLife improved profitability through a cleaner product mix and tighter cash discipline. The real opportunity could sit in stocks where similar margin progress is early and valuations may not fully reflect it.
-
Company 1 - 33% below our estimate - earns recurring fees for channeling long term capital into renewable projects and essential infrastructure that asset owners may find hard to reach directly.
-
Company 2 - 34% below our estimate - uses personalisation tools to guide subscribers toward fresh audio titles that lift engagement without matching increases in marketing spend.
-
Company 3 - 23% below our estimate - supplies diagnostic gear and components that utilities rely on as they upgrade aging grids to handle heavier and more complex electrical loads.
That is three of the list. See the full list of 190 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALIF-B.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
